FPIN's Help Desk Answers
Effectiveness of Pneumococcal Vaccines
Am Fam Physician. 2018 May 1;97(9):online.
How effective are pneumococcal polysaccharide vaccines in preventing pneumonia in adults?
The 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23) decreases the relative risk of community-acquired pneumonia in adults by 13%. The risk is reduced by 28% in the population that includes adults older than 65 years, those with lung disease, and those living in a nursing home. (Strength of Recommendation [SOR]: B, based on a meta-analysis of lower-quality randomized controlled trials [RCTs].) PPSV23 also lowers the risk of pneumonia in nursing home residents, but not in community-dwelling patients. (SOR: B, based on a meta-analysis of lower-quality RCTs.) PPSV23 should be given to all patients 65 years and older and to younger patients with comorbidities such as chronic heart or lung disease. (SOR: C, based on expert opinion.)
A 2016 systematic review and meta-analysis of seven RCTs (N = 156,010) evaluated the effectiveness of PPSV23 in preventing community-acquired pneumonia over two to seven years.1 The control groups received a placebo injection, influenza vaccine, or no intervention. Multiple groups were included in the studies: adults older than 65 years, persons 19 to 64 years of age at risk of pneumonia because of chronic lung disease or living in a nursing home, healthy military recruits 17 to 20 years of age, and adults with a history of community-acquired pneumonia. The diagnosis of pneumonia was made by clinical symptoms and chest radiography. PPSV23 decreased the risk of pneumonia compared with placebo (relative risk [RR] = 0.87; 95% confidence interval [CI], 0.76 to 0.98; number needed to treat [NNT] = 1,134). The effect was greater in adults older than 65 years, nursing home residents, and in those with lung disease (five trials, N = 3,287; RR = 0.72; 95% CI, 0.69 to 0.94). Limitations included lack of standardization for the diagnosis of pneumonia.
A 2016 meta-analysis of four RCTs (N = 29,218) investigated
1. Diao WQ, Shen N, Yu PX, Liu BB, He B. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496–1503.
2. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus FW. Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk—a systematic review and meta-analysis. PLoS One. 2016;11(1):e0146338.
3. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816–819.
Help Desk Answers provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (http://www.cebm.net).
The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to https://www.fpin.org or e-mail: email@example.com.
This series is coordinated by John E. Delzell Jr., MD, MSPH, Associate Medical Editor.
A collection of FPIN's Help Desk Answers published in AFP is available at https://www.aafp.org/afp/hda.
Want to use this article elsewhere? Get Permissions